Genome-Wide Variations of End Motif in Cell-Free DNA Fragments Distinguish Immunotherapy Responders from Non-Responders in Head and Neck Cancer: A Multi-Institute Prospective Study
This multi-institute prospective study demonstrates that a novel fragmentomic metric called the regional motif diversity score (rMDS), derived from cell-free DNA end motifs, robustly distinguishes immunotherapy responders from non-responders in head and neck cancer and predicts improved disease-free survival, outperforming established biomarkers like PD-L1 expression and tumor fraction.